Education
About Us
Working with TipRanks
Follow Us
Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
TRIB Stock Chart & Stats
$0.75
-$0.09(-10.05%)
At close: 4:00 PM EST
$0.75
-$0.09(-10.05%)
Day’s Range― - ―
52-Week Range$0.48 - $3.44
Previous CloseN/A
Volume141.89K
Average Volume (3M)136.14K
Market Cap
$12.86M
Enterprise Value$123.03M
Total Cash (Recent Filing)$1.34M
Total Debt (Recent Filing)$117.20M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Apr 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding18,710,333
10 Day Avg. Volume159,092
30 Day Avg. Volume136,139
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-2.25
Price to Sales (P/S)1.28
P/FCF Ratio-5.54
Enterprise Value/Market Cap9.57
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit7.30
Enterprise Value/Ebitda-6.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$59.50M
Bulls Say, Bears Say
Bulls Say
Large HIV Order And Operational TurnaroundA 9M-unit order tied to WHO-prequalified product and outsourced WHO-approved manufacturing demonstrates durable demand and scalable production. The sequential revenue jump and return to positive adjusted EBITDA signal operational leverage and improved unit economics that can sustain cash generation over multiple quarters.
Regulatory Clearances For High-capacity HbA1c SystemRegulatory approvals and a higher-throughput HbA1c column expand addressable share in the large, recurring $2B+ lab HbA1c market. Higher capacity and reduced downtime enhance lab economics, increase reagent consumable demand, and strengthen long-term platform positioning and margin sustainability.
WHO Approval For Outsourced ManufacturingWHO approval for outsourced manufacturing reduces unit cost and enables higher-volume production while preserving regulatory compliance. This structural cost reduction supports margin recovery, improves free-cash-flow potential, and aligns with management's transformation initiatives to restore profitability over the medium term.
Bears Say
Negative Shareholders' Equity And Elevated LeverageConsistent negative equity and rising debt materially weaken financial flexibility and increase solvency risk. With limited capital cushion, the company faces constraints on funding R&D, commercial expansion, or absorbing further operating shocks without dilutive or costly financing, raising long-term risk.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow mean the business cannot internally fund operations or growth. Reliance on external financing increases funding cost and dilution risk, limits ability to invest in commercialization or capex, and makes long-term execution contingent on continued external support.
Convertible Debt Restructuring Creates Major Dilution RiskEquitizing significant debt improves near-term liquidity but creates a structural overhang: potential issuance of tens of millions of ADSs can materially dilute existing equity, erode per-share economics, and deter long-term investors, complicating capital markets access and governance stability.
Trinity Biotech News
TRIB FAQ
What was Trinity Biotech Plc’s price range in the past 12 months?
Trinity Biotech Plc lowest stock price was $0.48 and its highest was $3.44 in the past 12 months.
What is Trinity Biotech Plc’s market cap?
Trinity Biotech Plc’s market cap is $12.86M.
When is Trinity Biotech Plc’s upcoming earnings report date?
Trinity Biotech Plc’s upcoming earnings report date is Apr 08, 2026 which is in 35 days.
How were Trinity Biotech Plc’s earnings last quarter?
Trinity Biotech Plc released its earnings results on Dec 11, 2025. The company reported -$0.274 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.274.
Is Trinity Biotech Plc overvalued?
According to Wall Street analysts Trinity Biotech Plc’s price is currently Overvalued.
Does Trinity Biotech Plc pay dividends?
Trinity Biotech Plc pays a Annually dividend of $1.1 which represents an annual dividend yield of N/A. See more information on Trinity Biotech Plc dividends here
What is Trinity Biotech Plc’s EPS estimate?
Trinity Biotech Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trinity Biotech Plc have?
Trinity Biotech Plc has 18,710,333 shares outstanding.
What happened to Trinity Biotech Plc’s price movement after its last earnings report?
Trinity Biotech Plc reported an EPS of -$0.274 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.14%.
Which hedge fund is a major shareholder of Trinity Biotech Plc?
Currently, no hedge funds are holding shares in TRIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Trinity Biotech Plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Technical Analysis
―
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.09% Mutual Funds
3.76% Other Institutional Investors
96.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---